London open The FTSE 100 is expected to open six points lower on Friday, having closed down 1.55% on Thursday at 8,474.74.

London stocks were set to edge lower at the open on Friday following heavy losses a day earlier, as investors continued to ...

As a first-line therapy, DS-1062/Keytruda had an ORR of 62%, compared to 50% with triple therapy with chemo, with a disease control rate (DCR) or 100% and ... ADC to follow Enhertu (trastuzumab ...

It is thought that around 100 people in England will be eligible ... AstraZeneca is celebrating two approvals for cancer drugs Imfinzi and Enhertu in the EU as it faces increased competition ...

AstraZeneca PLC (LSE:LON:AZN), a pharmaceutical giant with a market capitalization of $224 billion and an impressive gross profit margin of 82%, announced today that its drug Enhertu has been ...

AstraZeneca PLC (LSE:LON:AZN), a pharmaceutical giant with a market capitalization of $224 billion and an impressive gross profit margin of 82%, announced today that its drug Enhertu has been approved ...

The European Commission (EC) has approved Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) for use as a single agent to treat adults with unresectable or metastatic hormone ...

Daiichi Sankyo (DSNKY) and AstraZeneca’s Enhertu has been approved in the European Union as a monotherapy for the treatment of adult patients with unresectable or metastatic hor ...

(RTTNews) - AstraZeneca Plc. (AZN.L, AZN) and Daiichi Sankyo's (DSKYF.PK) Enhertu (trastuzumab deruxtecan) has been approved in the European Union as a treatment for adults with advanced breast ...

The Cambridge, England-based pharmaceuticals firm said Enhertu, or trastuzumab deruxtecan, has been approved in the EU as a therapy for adult patients with unresectable or metastatic hormone ...